However, the combination of olaparib with temozolomide or irinotecan showed significant responses in 80% of mice orthotopically engrafted with human Ewing’s sarcoma cells [52], and clinical trial data exploring combinations of PARP inhibitors in Ewing’s sarcoma are pending. The gene discussed is PARP1; the disease is Ewing sarcoma.